FrancophonIA/ELRC3.0 huggingface dataset:
English: EU/1/11/673/017 (14 film-coated tablets) EU/1/11/673/018 (28 film-coated tablets) EU/1/11/673/019 (30 film-coated tablets) EU/1/11/673/020 (56 film-coated tablets) EU/1/11/673/021 (56 x 1 film-coated tablets) EU/1/11/673/022 (84 film-coated tablets) EU/1/11/673/023 (90 film-coated tablets) EU/1/11/673/024 (98 film-coated tablets)
Slovenian: EU/1/11/673/017 (14 filmsko obloženih tablet) EU/1/11/673/018 (28 filmsko obloženih tablet) EU/1/11/673/019 (30 filmsko obloženih tablet) EU/1/11/673/020 (56 filmsko obloženih tablet) EU/1/11/673/021 (56 x 1 filmsko obloženih tablet) EU/1/11/673/022 (84 filmsko obloženih tablet) EU/1/11/673/023 (90 filmsko obloženih tablet) EU/1/11/673/024 (98 filmsko obloženih tablet)
English: Not known: aplastic anaemia, bone marrow depression, neutropenia/agranulocytosis, haemolytic anaemia, leucopenia, thrombocytopenia
Slovenian: Neznana pogostnost: aplastična anemija, zavora delovanja kostnega mozga, nevtropenija ali agranulocitoza, hemolitična anemija, levkopenija, trombocitopenija
English: Ifirmacombi should not be used in patients with severe renal impairment (creatinine clearance < 30 ml/min) (see section 4.3).
Slovenian: Pri bolnikih s hudo ledvično okvaro (kreatininski očistek < 30 ml/min) se ga ne sme uporabljati (glejte poglavje 4.3).
English: Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.
Slovenian: Bolniki morajo piti primerno količino tekočine, po uvedbi sočasnega jemanja pa je priporočljivo redno spremljanje ledvičnega delovanja.
English: Potassium-sparing diuretics, potassium supplements or potassium-containing salts substitutes should be co-administered cautiously with Ifirmacombi (see section 4.5).
Slovenian: Pri hkratnem zdravljenju z diuretiki, ki varčujejo kalij, pripravki s kalijem, nadomestki soli, ki vsebujejo kalij, in zdravilom Ifirmacombi je potrebna posebna previdnost (glejte poglavje 4.5).
English: Protect your skin from sun exposure and UV rays while taking Ifirmacombi.
Slovenian: Med jemanjem zdravila Ifirmacombi zaščitite kožo pred izpostavljenostjo soncu in UV-žarkom.
English: EU/1/11/673/001 (14 film-coated tablets) EU/1/11/673/002 (28 film-coated tablets) EU/1/11/673/003 (30 film-coated tablets) EU/1/11/673/004 (56 film-coated tablets) EU/1/11/673/005 (56 x 1 film-coated tablets) EU/1/11/673/006 (84 film-coated tablets) EU/1/11/673/007 (90 film-coated tablets) EU/1/11/673/008 (98 film-coated tablets)
Slovenian: EU/1/11/673/001 (14 filmsko obloženih tablet) EU/1/11/673/002 (28 filmsko obloženih tablet) EU/1/11/673/003 (30 filmsko obloženih tablet) EU/1/11/673/004 (56 filmsko obloženih tablet) EU/1/11/673/005 (56 x 1 filmsko obloženih tablet) EU/1/11/673/006 (84 filmsko obloženih tablet) EU/1/11/673/007 (90 filmsko obloženih tablet) EU/1/11/673/008 (98 filmsko obloženih tablet)
English: Irbesartan/hydrochlorothiazide
Slovenian: Irbesartan in hidroklorotiazid
English: Reporting of side effects
Slovenian: Dodatni podatki o posameznih učinkovinah
English: Blood and lymphatic system disorders:
Slovenian: Bolezni krvi in limfatičnega sistema
English: EU/1/11/673/009 (14 film-coated tablets) EU/1/11/673/010 (28 film-coated tablets) EU/1/11/673/011 (30 film-coated tablets) EU/1/11/673/012 (56 film-coated tablets) EU/1/11/673/013 (56 x 1 film-coated tablets) EU/1/11/673/014 (84 film-coated tablets) EU/1/11/673/015 (90 film-coated tablets) EU/1/11/673/016 (98 film-coated tablets)
Slovenian: EU/1/11/673/009 (14 filmsko obloženih tablet) EU/1/11/673/010 (28 filmsko obloženih tablet) EU/1/11/673/011 (30 filmsko obloženih tablet) EU/1/11/673/012 (56 filmsko obloženih tablet) EU/1/11/673/013 (56 x 1 filmsko obloženih tablet) EU/1/11/673/014 (84 filmsko obloženih tablet) EU/1/11/673/015 (90 filmsko obloženih tablet) EU/1/11/673/016 (98 filmsko obloženih tablet)
English: Additional information on hydrochlorothiazide interactions: When administered concurrently, the following medicinal products may interact with thiazide diuretics:
Slovenian: Dodatni podatki o medsebojnem delovanju s hidroklorotiazidom Ob sočasnem jemanju se lahko pojavijo interakcije med tiazidnimi diuretiki in naslednjimi v nadaljevanju navedenimi zdravili.
English: The potassium-depleting effect of hydrochlorothiazide is attenuated by the potassium-sparing effect of irbesartan.
Slovenian: Zmanjševanje kalija, ki ga povzroča hidroklorotiazid, omili delovanje irbesartana, ki varčuje s kalijem.
English: A cumulative doseresponse relationship was demonstrated with an adjusted OR 2.1 (95% CI: 1.7-2.6) increasing to OR 3.9 (3.0-4.9) for high use (~25,000 mg) and OR 7.7 (5.7-10.5) for the highest cumulative dose (~100,000 mg) (see also section 4.4).
Slovenian: Razmerje med kumulativnim odmerkom in odzivom so dokazali s tem, da se je prilagojeni OR z 2,1 (95-odstotni IZ: 1,7-2,6), zvišal na 3,9 (3,0-4,9) pri velikih odmerkih (~
English: Medicinal products affecting potassium:
Slovenian: Zdravila, ki vplivajo na kalij
English: Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg. A less than proportional increase in oral absorption at doses beyond 600 mg was observed; the mechanism for this is unknown.
Slovenian: Po zaužitju odmerka, večjega od 600 mg, ne pride do proporcionalnega povečanja absorpcije; mehanizem tega pojava ni znan.
English: There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure).
Slovenian: Dvojna blokada sistema renin-angiotenzin-aldosteron (RAAS) Obstajajo dokazi, da sočasna uporaba zaviralcev ACE, antagonistov receptorjev angiotenzina II ali aliskirena poveča tveganje za hipotenzijo, hiperkaliemijo in zmanjšano delovanje ledvic (vključno z akutno odpovedjo ledvic).
English: There were 0.6% and 0% of patients with hypotension and 2.8% and 3.1% of patients with dizziness as adverse reactions reported in the combination and monotherapy groups, respectively.
Slovenian: V skupini, ki je prejemala kombinacijo učinkovin, so pri 0,6 % bolnikov poročali o hipotenziji in pri 2,8 % bolnikov o omotici.
English: Presumably through blockade of the renin-angiotensin-aldosterone system, co-administration of irbesartan tends to reverse the potassium loss associated with these diuretics.
Slovenian: Med hkratnim zdravljenjem z irbesartanom se verjetno zaradi blokade reninsko-angiotenzinsko-aldosteronskega sistema zmanjša izplavljanje kalija, ki ga povzročajo ti diuretiki.
English: Not known: cough
Slovenian: Neznana pogostnost: kašelj
English: nausea/vomiting diarrhoea dyspepsia, dysgeusia
Slovenian: navzea/bruhanje driska dispepsija, motnje okusa
English: Not known: cases of hypersensitivity reactions such as angioedema, rash, urticaria
Slovenian: Bolezni imunskega sistema Neznana pogostnost: primeri preobčutljivostnih reakcij, kot so angioedem, izpuščaj, urtikarija
English: Because no information is available regarding the use of Ifirmacombi during breast-feeding, Ifirmacombi is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
Slovenian: Podatkov o uporabi zdravila Ifirmacombi med dojenjem ni na voljo, zato uporaba zdravila Ifirmacombi med dojenjemni priporočljiva.
English: Peak plasma concentration occurs at 1.5-2 hours after oral administration for irbesartan and 1-2.5 hours for hydrochlorothiazide.
Slovenian: Največja plazemska koncentracija irbesartana se doseže 1,5 ure do 2 uri po peroralnem jemanju, največja plazemska koncentracija hidroklorotiazida pa čez 1 uro do 2,5 ure.
English: Acute Myopia and Secondary Acute Angle-Closure Glaucoma:
Slovenian: Akutna kratkovidnost in sekundarni akutni glavkom z zaprtim zakotjem:
English: When assessed by ambulatory blood pressure monitoring, the combination 150 mg irbesartan and 12.5 mg hydrochlorothiazide once daily produced consistent reduction in blood pressure over the 24 hours period with mean 24-hour placebo-subtracted systolic/diastolic reductions of 15.8/10.0 mmHg.
Slovenian: Ocenjevanje krvnega tlaka pri bolnikih, ki so enkrat na dan dobivali po 150 mg irbesartana in 12,5 mg hidroklorotiazida, pa je pokazalo, da se je krvni tlak v obdobju 24 ur konstantno zniževal in da je srednje 24-urno znižanje sistoličnega krvnega tlaka za 15,8 mm Hg, diastoličnega pa za 10,0 mm Hg večje kot pri placebu.
English: However, in patients with mild to moderate renal impairment (creatinine clearance ≥ 30 ml/min but < 60 ml/min) this fixed dose combination should be administered with caution.
Slovenian: Bolnikom z ledvično okvaro, pri katerih je ledvični očistek ≥ 30 ml/min, odmerka zdravila ni treba prilagajati, kljub temu pa ga je treba bolnikom z blago ali zmerno ledvično okvaro (kreatininski očistek ≥30 ml/min, toda < 60 ml/min) dajati zelo previdno.
English: Ifirmacombi 150 mg/12.5 mg film-coated tablets Ifirmacombi 300 mg/12.5 mg film-coated tablets Ifirmacombi 300 mg/25 mg film-coated tablets
Slovenian: Ifirmacombi 150 mg/12,5 mg filmsko obložene tablete Ifirmacombi 300 mg/12,5 mg filmsko obložene tablete Ifirmacombi 300 mg/25 mg filmsko obložene tablete
English: Thiazides may increase the risk of adverse effects caused by amantadine.
Slovenian: Zaradi uporabe tiazidnih diuretikov se poveča nevarnost pojava neželenih učinkov amantadina.
English: ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.
Slovenian: Zato se pri bolnikih z diabetično nefropatijo zaviralcev ACE in antagonistov receptorjev angiotenzina II ne sme uporabljati sočasno.
English: The trough to peak effects measured by cuff during office visits were 68% and 76% for Ifirmacombi 150 mg/12.5 mg and Ifirmacombi 300 mg/12.5 mg, respectively.
Slovenian: Pri merjenju z manšeto v ambulanti je bilo pri bolnikih, ki so jemali zdravilo Ifirmacombi 150 mg/12,5 mg, to razmerje 68 %, pri tistih, ki so dobivali zdravilo Ifirmacombi 300 mg/12,5 mg, pa 76 %.
English: Ifirmacombi 150 mg/12.5 mg film-coated tablets Pale pink, biconvex, oval, film-coated tablets.
Slovenian: Ifirmacombi 150 mg/12,5 mg filmsko obložene tablete Bledo roza, izbočene, ovalne, filmsko obložene tablete.
English: The recommended dose of Ifirmacombi 150 mg/12.5 mg is one tablet a day.
Slovenian: Odmerjanje zdravila Ifirmacombi 150 mg/12,5 mg Priporočeni odmerek zdravila Ifirmacombi 150 mg/12,5 mg je ena tableta na dan.
English: When measured by ambulatory blood pressure monitoring, the trough to peak effects of Ifirmacombi 150 mg/12.5 mg were 100%.
Slovenian: Med 24-urnim merjenjem krvnega tlaka pri bolnikih, ki so dobivali zdravilo Ifirmacombi 150 mg/12,5 mg, je bilo razmerje med najmanjšim in največjim učinkom 100 %.
English: No dosage adjustment is necessary in older people.
Slovenian: Starejšim bolnikom odmerka ni treba prilagajati.
English: As is the case with other medicinal products that affect the renin-angiotensin system, black hypertensive patients have notably less response to irbesartan monotherapy.
Slovenian: Pri temnopoltih bolnikih s hipertenzijo je odziv na samostojno zdravljenje z irbesartanom pomembno manjši, podobno kot pri drugih zdravilih, ki vplivajo na reninsko-angiotenzinski sistem.
English: In patients not adequately controlled on 25 mg hydrochlorothiazide alone, the addition of irbesartan gave an added placebo-subtracted systolic/diastolic mean reduction of 11.1/7.2 mmHg.
Slovenian: Pri bolnikih, pri katerih se krvni tlak med zdravljenjem s 25 mg hidroklorotiazida ni dovolj znižal, se je sistolični krvni tlak po dodatku irbesartana dodatno znižal za povprečno 11,1 mm Hg glede na placebo, diastolični pa za 7,2 mm Hg.
English: Latent diabetes mellitus may become manifest during thiazide therapy.
Slovenian: Med zdravljenjem s tiazidnimi diuretiki lahko latentna sladkorna bolezen preide v manifestno.
English: ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.
Slovenian: Pri bolnikih z diabetično nefropatijo se zaviralcev ACE in antagonistov receptorjev angiotenzina II ne sme uporabljati sočasno.
English: Ifirmacombi 150 mg/12.5 mg will usually be prescribed by your doctor when your previous treatment did not reduce your blood pressure enough.
Slovenian: Zdravnik vam je zdravilo Ifirmacombi 150 mg/12,5 mg predpisal zato, ker se vaš krvni tlak med dosedanjim zdravljenjem ni dovolj znižal.
English: Ifirmacombi 300 mg/25 mg: mannitol, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, sodium starch glycolate, talc, macrogol 6000, hydrogenated castor oil in the tablet core and polyvinyl alcohol, titanium dioxide (E171), macrogol, talc, yellow iron oxide (E172) and red iron oxide (E172) in the film-coating.
Slovenian: Ifirmacombi 300 mg/25 mg: manitol, hidroksipropilceluloza, nizko substituirana hidroksipropilceluloza, natrijev karboksimetilškrob, smukec, makrogol 6000 in hidrogenirano ricinusovo olje v jedru tablete ter polivinilalkohol, titanov dioksid (E171), makrogol, smukec, rumeni železov oksid (E172) in rdeči železov oksid (E172) v filmski oblogi.
English: Nondepolarizing skeletal muscle relaxants (e.g. tubocurarine): the effect of nondepolarizing skeletal muscle relaxants may be potentiated by hydrochlorothiazide;
Slovenian: Nedepolarizirajoči relaksanti skeletnega mišičja (npr. tubokurarin):
English: Although equivocal evidence for a genotoxic or carcinogenic effect was found in some experimental models, the extensive human experience with hydrochlorothiazide has failed to show an association between its use and an increase in neoplasms.
Slovenian: Na nekaj poskusnih modelih so opazili genotoksično in karcinogeno delovanje hidroklorotiazida, vendar dokazi niso zanesljivi.
English: There is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists.
Slovenian: Stenoza ledvične arterije - renovaskularna hipertenzija Pri bolnikih z obojestransko zožitvijo ledvičnih arterij ali zožitvijo arterije delujoče ledvice se med jemanjem zaviralcev angiotenzinske konvertaze ali antagonistov angiotenzina II poveča nevarnost pojava hude hipotenzije in motnje v ledvičnem delovanju.
English: Not known: vertigo, paraesthesia, light-headedness, restlessness
Slovenian: Neznana pogostnost: vrtoglavica, parestezija, omotica, nemir
English: Ifirmacombi 300 mg/12.5 mg: mannitol, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, sodium starch glycolate, talc, macrogol 6000, hydrogenated castor oil in the tablet core and polyvinyl alcohol, titanium dioxide (E171), macrogol, talc in the film-coating.
Slovenian: Ifirmacombi 300 mg/12,5 mg: manitol, hidroksipropilceluloza, nizko substituirana hidroksipropilceluloza, natrijev karboksimetilškrob, smukec, makrogol 6000 in hidrogenirano ricinusovo olje v jedru tablete ter polivinilalkohol, titanov dioksid (E171), makrogol in smukec v filmski oblogi.
English: Ifirmacombi 150 mg/12.5 mg: mannitol, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, sodium starch glycolate, talc, macrogol 6000, hydrogenated castor oil in the tablet core and polyvinyl alcohol, titanium dioxide (E171), macrogol, talc, yellow iron oxide (E172) and red iron oxide (E172) in the film-coating.
Slovenian: Ifirmacombi 150 mg/12,5 mg: manitol, hidroksipropilceluloza, nizko substituirana hidroksipropilceluloza, natrijev karboksimetilškrob, smukec, makrogol 6000 in hidrogenirano ricinusovo olje v jedru tablete ter polivinilalkohol, titanov dioksid (E171), makrogol, smukec, rumeni železov oksid (E172) in rdeči železov oksid (E172) v filmski oblogi.
English: Hydroxypropylcellulose Hydroxypropylcellulose, low-substituted Sodium starch glycolate Talc
Slovenian: Jedro tablete: manitol hidroksipropilceluloza nizko substituirana hidroksipropilceluloza natrijev karboksimetilškrob smukec makrogol 6000 hidrogenirano ricinusovo olje
English: Increases in cholesterol and triglyceride levels have been associated with thiazide diuretic therapy; however at the 12.5 mg dose contained in Ifirmacombi, minimal or no effects were reported.
Slovenian: Pri bolnikih, ki so jemali po 12,5 mg hidroklorotiazida, kolikor ga vsebuje zdravilo Ifirmacombi, je bil ta učinek zelo majhen ali pa ga sploh ni bilo.
English: Ifirmacombi 150 mg/12.5 mg film-coated tablets Ifirmacombi 300 mg/12.5 mg film-coated tablets Ifirmacombi 300 mg/25 mg film-coated tablets Irbesartan/Hydrochlorothiazide
Slovenian: Ifirmacombi 150 mg/12,5 mg filmsko obložene tablete Ifirmacombi 300 mg/12,5 mg filmsko obložene tablete Ifirmacombi 300 mg/25 mg filmsko obložene tablete irbesartan/hidroklorotiazid
English: Periodic monitoring of serum potassium is recommended when Ifirmacombi is administered with medicinal products affected by serum potassium disturbances (e.g. digitalis glycosides, antiarrhythmics).
Slovenian: Zdravila, na katera vplivajo motnje serumske koncentracije kalija Med sočasnim zdravljenjem z zdravilom Ifirmacombi in drugimi zdravili, katerih delovanje vpliva na motnje serumske koncentracije kalija (npr. z digitalisovimi glikozidi, antiaritmiki), je priporočeno redno preverjanje kalija v serumu.
English: The recommended dose of Ifirmacombi 300 mg/25 mg is one tablet a day.
Slovenian: Odmerjanje zdravila Ifirmacombi 300 mg/25 mg Priporočeni odmerek zdravila Ifirmacombi 300 mg/25 mg je ena tableta na dan. Tega odmerka se ne sme povečati.
English: Not known: pancreatitis, anorexia, diarrhoea, constipation, gastric irritation, sialadenitis, loss of appetite
Slovenian: Neznana pogostnost: vnetje trebušne slinavke, anoreksija, driska, obstipacija, draženje želodca, vnetje žleze slinavke, izguba apetita
English: As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.
Slovenian: Stenoza aortne in mitralne zaklopke, obstruktivna hipertrofična kardiomiopatija Tako kot pri zdravljenju z drugimi vazodilatatorji je tudi pri bolnikih z aortno ali mitralno stenozo ali obstruktivno hipertrofično kardiomiopatijo potrebna posebna previdnost.
English: Non-steroidal anti-inflammatory drugs: the administration of a non-steroidal anti-inflammatory drug may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics in some patients;
Slovenian: Pri nekaterih bolnikih se lahko med hkratnim jemanjem nesteroidnih protivnetnih zdravil zmanjša diuretični, natriuretični in antihipertenzijski učinek tiazidnih diuretikov.
English: Not known: weakness, muscle spasm
Slovenian: Neznana pogostnost: oslabelost, mišični krč
English: Once daily dosing with 150 mg irbesartan and 12.5 mg hydrochlorothiazide gave systolic/diastolic mean placebo-adjusted blood pressure reductions at trough (24 hours post-dosing) of 12.9/6.9 mmHg in patients with mild-to-moderate hypertension.
Slovenian: Pri bolnikih z blago do zmerno hipertenzijo, ki so enkrat na dan dobili po 150 mg irbesartana in 12,5 mg hidroklorotizida, se je sistolični krvni tlak 24 ur po zaužitju odmerka znižal za 12,9 mm Hg bolj kot po placebu, diastolični pa za 6,9 mm Hg.
English: Hydrochlorothiazide
Slovenian: Hidroklorotiazid:
English: The recomended dose of Ifirmacombi 300 mg /12.5 mg is one tablet a day.
Slovenian: Odmerjanje zdravila Ifirmacombi 300 mg/12,5 mg Priporočeni odmerek zdravila Ifirmacombi 300 mg/12,5 mg je ena tableta na dan.
English: Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors.
Slovenian: Med sočasnim jemanjem litija in zaviralcev angiotenzinske konvertaze so opazili reverzibilno povečanje serumske koncentracije litija in toksičnost.
English: Not known: cardiac arrhythmias
Slovenian: Neznana pogostnost: aritmija
English: Thiazides should be used with caution in patients with impaired hepatic function.
Slovenian: Pri bolnikih z okvarjenom jetrnim delovanjem je treba tiazidne diuretike uporabljati zelo previdno.
English: Not known: postural hypotension
Slovenian: Neznana pogostnost: ortostatska hipotenzija
English: No teratogenic effects were seen in rats given irbesartan and hydrochlorothiazide in combination at doses that produced maternal toxicity.
Slovenian: Pri podganjih samicah se teratogeni učinki kljub toksičnim odmerkom kombinacije irbesartana in hidroklorotiazida niso pojavili.
English: How to store Ifirmacombi
Slovenian: Shranjevanje zdravila Ifirmacombi
English: Uncommon: Not known:
Slovenian: Občasni: Neznana pogostnost:
English: Ifirmacombi 300 mg/25 mg film-coated tablets Pale pink, biconvex, capsule shaped, film-coated tablets.
Slovenian: Ifirmacombi 300 mg/25 mg filmsko obložene tablete Bledo roza, izbočene, filmsko obložene tablete v obliki kapsule.
English: No significant pharmacokinetic or pharmacodynamic interactions were observed when irbesartan was coadministered with warfarin, a medicinal product metabolised by CYP2C9.
Slovenian: Pri sočasnem jemanju irbesartana in varfarina, zdravila, ki se presnavlja prek CYP2C9, niso opazili nobenih pomembnih farmakokinetičnih in farmakodinamičnih interakcij.
English: Psychiatric disorders:
Slovenian: Psihiatrične motnje
English: Ifirmacombi 300 mg/25 mg will usually be prescribed by your doctor when your previous treatment did not reduce your blood pressure enough.
Slovenian: Zdravnik vam je zdravilo Ifirmacombi 300 mg/25 mg predpisal zato, ker se vaš krvni tlak med dosedanjim zdravljenjem ni dovolj znižal.
English: The mean baseline blood pressure was approximately 172/113 mmHg in each treatment group and decreases of SeSBP/SeDBP at five weeks were 30.8/24.0 mmHg and 21.1/19.3 mmHg for irbesartan/hydrochlorothiazide and irbesartan, respectively (p < 0.0001).
Slovenian: Po petih zdravljenja se je v skupini, ki je prejemala kombinacijo irbesartana in hidroklorotiazida, zmanjšala za 30,8/24,0 mm Hg (sistolični in diastolični krvni tlak v sedečem položaju), v skupini, ki je prejemala irbesartan, pa za 21,1/19,3 mm Hg (p < 0,0001).
English: Although not specifically studied with the Ifirmacombi, rebound hypertension has not been seen with either irbesartan or hydrochlorothiazide.
Slovenian: Posebnih študij z zdravilom Ifirmacombi ni, kljub temu pa povratnega zvišanja krvnega tlaka pri bolnikih, ki so jemali bodisi irbesartan bodisi hidroklorotiazid, po prenehanju jemanja zdravila niso opazili.
English: Ifirmacombi 300 mg/12.5 mg will usually be prescribed by your doctor when your previous treatment did not reduce your blood pressure enough.
Slovenian: Zdravnik vam je zdravilo Ifirmacombi 300 mg/12,5 mg predpisal zato, ker se vaš krvni tlak med dosedanjim zdravljenjem ni dovolj znižal.
English: Hepatobiliary disorders:
Slovenian: Digitalisovi glikozidi:
English: Ifirmacombi 300 mg/12.5 mg film-coated tablets White, biconvex, capsule shaped, film-coated tablets.
Slovenian: Ifirmacombi 300 mg/12,5 mg filmsko obložene tablete Bele, izbočene, filmsko obložene tablete v obliki kapsule.
English: The addition of 12.5 mg hydrochlorothiazide to 300 mg irbesartan once daily in patients not adequately controlled on 300 mg irbesartan alone resulted in further placebo-corrected diastolic blood pressure reductions at trough (24 hours post-dosing) of 6.1 mmHg.
Slovenian: Diastolični krvni tlak se je pri bolnikih, pri katerih zdravljenje s 300 mg irbesartana ni bilo dovolj učinkovito in so začeli jemati tudi po 12,5 mg hidroklorotiazida enkrat na dan, 24 ur po zaužitju odmerka znižal za povprečno 6,1 mm Hg bolj kot po uporabi placeba.
English: Not known: fever
Slovenian: Neznana pogostnost: zvišana telesna temperatura
English: Ifirmacombi 300 mg/25 mg tablets Irbesartan/Hydrochlorothiazide
Slovenian: Ifirmacombi 300 mg/25 mg tablete irbesartan/hidroklorotiazid